VIR Vir Biotechnology, Inc.: Year-over-year earnings per share growth for the last twelve months

Graphic logo of Vir Corp (VIR)

Vir Biotechnology, Inc. (VIR) relies on external contractors for testing and drug manufacturing. The quarterly earnings per share trend illustrates the impact of this strategy, where 52.10 reflects the current value of the metric. The niche's safe haven status guarantees stable demand, while the loyalty of patients with chronic hepatitis and FDA support determine the company's long-term growth potential.

VIR: vir.bio Year-over-year earnings per share growth for the last twelve months 07/04/2022 - 11/15/2026

Vir Biotechnology (VIR) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Summary company analytics:Vir Bio - VIR
Manufactured product of vir.bio

Market expectations for Vir Biotechnology, Inc. (VIR) often outpace the actual speed of drug commercialization. The quarterly EPS growth trend measures earnings per share dynamics, eliminating time gaps between official reports. This indicator captures the immediate market reaction to fundamental changes. For the biotech sector, such volatility reflects the risks associated with prolonged vaccine licensing. The stability of this metric confirms the effectiveness of the company's patent protection and scientific foundation.

Direct competitors

Gilead Sciences Inc (GILD) - Year-over-year earnings per share growth for the last twelve months|Cidara - Year-over-year earnings per one share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months NVAX|Quarterly EPS earnings growth curevac.com|Year-over-year earnings per share growth for the last twelve months Valneva Corp (VALN)|Year-over-year net earnings per share change for the last twelve months SIGA Technologies Inc|Year-over-year earnings per share growth for the last twelve months Emergent Bio EBS|Quarterly EPS earnings growth Atea Pharmaceuticals AVIR|IVVD - Year-over-year earnings per share growth for the last twelve months|ENTA (Enanta Pharmaceuticals) - Year-over-year earnings per share growth for the last 12 months|INO (Inovio) - Year-over-year net earnings per share growth for the last 12 months|HLVX (HilleVax Inc) - Year-over-year earnings per share growth for the last twelve months|KLRS (Kalaris Therapeutics Inc.) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months DYAI (Dyadic International)|Year-over-year net earnings per share growth for the last 12 months NNVC (NanoViricides)|TLPH (Talphera, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Cocrystal Pharma Inc COCP|Year-over-year earnings per one share growth for the last 12 months TRAW|Dogwood Therapeutics Inc. - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Qualigen Corp|ALVR (AlloVir Bio) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share growth for the last 12 months VBI Vaccines, Inc.|VIRI (virios.com) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months VXRT (Vaxart, Inc.)